Motor neuron disease-frontotemporal dementia: a clinical continuum

References

• Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 1981;104(2):217-47
   PubMed Web of Science ®Google Scholar
• Lillo P, Savage S, Mioshi E, et al. Amyotrophic lateral sclerosis and frontotemporal dementia: a behavioural and cognitive continuum. Amyotroph Lateral Scler 2012;13(1):102-9
   PubMed Web of Science ®Google Scholar
• Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain 2011;134(Pt 9):2582-94
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science 2006;314(5796):130-3
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A Hexanucleotide Repeat Expansion in C9ORF72 is the cause of chromosome 9p21-Linked ALS-FTD. Neuron 2011;72(2):257-68
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC Hexanucleotide repeat in noncoding region of C9ORF72 Causes chromosome 9p-Linked FTD and ALS. Neuron 2011;72(2):245-56
   PubMed Web of Science ®Google Scholar
• Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population‐based study. Brain 2003;126(9):2016-22
   PubMed Web of Science ®Google Scholar
• Ratnavalli E, Brayne C, Dawson K, et al. The prevalence of frontotemporal dementia. Neurology 2002;58(11):1615-21
   PubMed Web of Science ®Google Scholar
• Gislason TB, Sjögren M, Larsson L, et al. The prevalence of frontal variant frontotemporal dementia and the frontal lobe syndrome in a population based sample of 85 year olds. J Neurol Neurosurg Psychiatry 2003;74(7):867-71
   PubMed Web of Science ®Google Scholar
• Knopman DS, Petersen RC, Edland SD, et al. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology 2004;62(3):506-8
   PubMed Web of Science ®Google Scholar
• Mercy L, Hodges JR, Dawson K, et al. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology 2008;71(19):1496-9
   PubMed Web of Science ®Google Scholar
• Snowden JS, Neary D, Mann DMA. Fronto-temporal lobar degeneration: fronto-temporal dementia, progressive aphasia, semantic dementia. 1996; Churchill Livingstone
   Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76(11):1006-14
   PubMed Web of Science ®Google Scholar
• Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008;63(6):709-19
   PubMed Web of Science ®Google Scholar
• Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011;10(2):162-72
   PubMed Web of Science ®Google Scholar
• Hornberger M, Piguet O, Graham AJ, et al. How preserved is episodic memory in behavioral variant frontotemporal dementia? Neurology 2010;74(6):472-9
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134(Pt 9):2456-77
   PubMed Web of Science ®Google Scholar
• Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain 1992;115(Pt 6):1783-806
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76(11):1006-14
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Warren JD. Phenomenology and anatomy of abnormal behaviours in primary progressive aphasia. J Neurol Sci 2010;293(1):35-8
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81(4):385-90
   PubMed Web of Science ®Google Scholar
• Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377(9769):942-55
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006;66(5):647-53
   PubMed Web of Science ®Google Scholar
• Talbot K. Motor neuron disease: the bare essentials. Pract Neurol 2009;9(5):303-9
   PubMedGoogle Scholar
• Mioshi E, Caga J, Lillo P, et al. Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology 2014;82(2):149-55
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2000;1(5):293-9
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124:96-107
   PubMed Web of Science ®Google Scholar
• Nodera H, Izumi Y, Kaji R. [New diagnostic criteria of ALS (Awaji criteria)]. Brain Nerve 2007;59(10):1023-9
   PubMedGoogle Scholar
• Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci 2014;37(8):433-42
   PubMed Web of Science ®Google Scholar
• Caga J, Ramsey E, Hogden A, et al. A longer diagnostic interval is a risk for depression in amyotrophic lateral sclerosis. Palliat Support Care 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Eisen A, Swash M. Clinical neurophysiology of ALS. Clin Neurophysiol 2001;112(12):2190-201
   PubMed Web of Science ®Google Scholar
• Simon NG, Kiernan MC. Fasciculation anxiety syndrome in clinicians. J Neurol 2013;260(7):1743-7
   PubMed Web of Science ®Google Scholar
• Wilbourn AJ. The “split hand syndrome”. Muscle Nerve 2000;23(1):138-8
   PubMed Web of Science ®Google Scholar
• Menon P, Kiernan MC, Yiannikas C, et al. Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol 2013;124(2):410-16
   PubMed Web of Science ®Google Scholar
• Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006;129(9):2436-46
   PubMed Web of Science ®Google Scholar
• Vucic S, Ziemann U, Eisen A, et al. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry 2013;84(10):1161-70
   PubMed Web of Science ®Google Scholar
• Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008;131(6):1540-50
   PubMed Web of Science ®Google Scholar
• Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2012;83(1):102-8
   PubMed Web of Science ®Google Scholar
• Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011;76(14):1263-9
   PubMed Web of Science ®Google Scholar
• Raaphorst J, van Tol MJ, Groot PF, et al. Prefrontal involvement related to cognitive impairment in progressive muscular atrophy. Neurology 2014;83(9):818-25
   PubMed Web of Science ®Google Scholar
• Stukovnik V, Zidar J, Podnar S, et al. Amyotrophic lateral sclerosis patients show executive impairments on standard neuropsychological measures and an ecologically valid motor-free test of executive functions. J Clin Exp Neuropsychol 2010;32(10):1095-109
   PubMed Web of Science ®Google Scholar
• Taylor LJ, Brown RG, Tsermentseli S, et al. Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2013;84(5):494-8
   PubMed Web of Science ®Google Scholar
• Bak TH, O’Donovan DG, Xuereb JH, et al. Selective impairment of verb processing associated with pathological changes in Brodmann areas 44 and 45 in the motor neurone disease-dementia-aphasia syndrome. Brain 2001;124(Pt 1):103-20
   PubMed Web of Science ®Google Scholar
• Abrahams S. Social cognition in amyotrophic lateral sclerosis. Neurodegener Dis Manag 2011;1(5):397-405
   Google Scholar
• Girardi A, Macpherson SE, Abrahams S. Deficits in emotional and social cognition in amyotrophic lateral sclerosis. Neuropsychology 2011;25(1):53-65
   PubMed Web of Science ®Google Scholar
• Cavallo M, Adenzato M, Macpherson SE, et al. Evidence of social understanding impairment in patients with amyotrophic lateral sclerosis. PLoS One 2011;6(10):e25948
   Web of Science ®Google Scholar
• Lillo P, Mioshi E, Hodges JR. Caregiver burden in amyotrophic lateral sclerosis is more dependent on patients’ behavioral changes than physical disability: a comparative study. BMC Neurol 2012;12:156
   PubMed Web of Science ®Google Scholar
• Lillo P, Garcin B, Hornberger M, et al. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol 2010;67(7):826-30
   PubMedGoogle Scholar
• Mioshi E, Hsieh S, Caga J, et al. A novel tool to detect behavioural symptoms in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014;15(3-4):298-304
   PubMed Web of Science ®Google Scholar
• Kertesz A, McMonagle P, Blair M, et al. The evolution and pathology of frontotemporal dementia. Brain 2005;128(Pt 9):1996-2005
   PubMed Web of Science ®Google Scholar
• Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004;56(3):399-406
   PubMed Web of Science ®Google Scholar
• Josephs KA, Parisi JE, Knopman DS, et al. Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol 2006;63(4):506-12
   PubMedGoogle Scholar
• Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002;59(7):1077-9
   PubMed Web of Science ®Google Scholar
• Byrne S, Elamin M, Bede P, Hardiman O. Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2012;83(4):365-7
   PubMed Web of Science ®Google Scholar
• Byrne S, Bede P, Elamin M, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011;12(3):157-9
   PubMed Web of Science ®Google Scholar
• Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011;7(11):603-15
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gijselinck I, Dillen L, et al. A Pan-European Study of the C9orf72 Repeat Associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 2013;34(2):363-73
   PubMed Web of Science ®Google Scholar
• Le Ber I, van der Zee J, Hannequin D, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 2007;28(9):846-55
   PubMed Web of Science ®Google Scholar
• Goedert M, Crowther RA, Spillantini MG. Tau mutations cause frontotemporal dementias. Neuron 1998;21(5):955-8
   PubMed Web of Science ®Google Scholar
• Van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 2008;7(10):965-74
   PubMed Web of Science ®Google Scholar
• Boeve BF, Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 2008;65(4):460-4
   PubMedGoogle Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362(6415):59-62
   PubMed Web of Science ®Google Scholar
• Canosa A, Calvo A, Moglia C, et al. A familial ALS case carrying a novel p. G147C SOD1 heterozygous missense mutation with non-executive cognitive impairment. J Neurol Neurosurg Psychiatry 2014;85(12):1437-9
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281(5384):1851-4
   PubMed Web of Science ®Google Scholar
• Nishimura AL, Mitne-Neto M, Silva HC, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004;75(5):822-31
   PubMed Web of Science ®Google Scholar
• Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465(7295):223-6
   PubMed Web of Science ®Google Scholar
• Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and’sporadic’amyotrophic lateral sclerosis. Nat Genet 2006;38(4):411-13
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130-3
   PubMed Web of Science ®Google Scholar
• Buratti E, Baralle FE. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol 2010;7(4):420-9
   PubMed Web of Science ®Google Scholar
• Blair IP, Williams KL, Warraich ST, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 2010;81(6):639-45
   PubMed Web of Science ®Google Scholar
• Van Langenhove T, van der Zee J, Sleegers K, et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 2010;74(5):366-71
   PubMed Web of Science ®Google Scholar
• van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013;12(10):978-88
   PubMed Web of Science ®Google Scholar
• Galimberti D, Arosio B, Fenoglio C, et al. incomplete penetrance of the C9ORF72 hexanucleotide repeat expansions: frequency in a cohort of geriatric non-demented subjects. J Alzheimers Dis 2014;39(1):19-22
   PubMed Web of Science ®Google Scholar
• Cruts M, Gijselinck I, Van Langenhove T, et al. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci 2013;36(8):450-9
   PubMed Web of Science ®Google Scholar
• Majounie E, Abramzon Y, Renton AE, et al. Repeat expansion in C9ORF72 in Alzheimer’s disease. N Engl J Med 2012;366(3):283-4
   PubMed Web of Science ®Google Scholar
• Lesage S, Le Ber I, Condroyer C, et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 2013;136(2):385-91
   PubMed Web of Science ®Google Scholar
• Majounie E, Abramzon Y, Renton AE, et al. Large C9orf72 repeat expansions are not a common cause of Parkinson’s disease. Neurobiol Aging 2012;33(10): 2527.e1–2
   Web of Science ®Google Scholar
• Goldman JS, Quinzii C, Dunning-Broadbent J, et al. Multiple System Atrophy and Amyotrophic Lateral Sclerosis in a Family With Hexanucleotide Repeat Expansions in C9orf72. JAMA neurology 2014;71(6):771-4
   PubMed Web of Science ®Google Scholar
• Nuytemans K, Inchausti V, Beecham GW, et al. Absence of C9ORF72 expanded or intermediate repeats in autopsy‐confirmed Parkinson’s disease. Mov Disord 2014;29(6):827-30
   PubMed Web of Science ®Google Scholar
• Scholz SW, Majounie E, Revesz T, et al. Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. Neurobiol Aging 2014;36(2):1223.e1-2
   Web of Science ®Google Scholar
• Murray ME, DeJesus-Hernandez M, Rutherford NJ, et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 2011;122(6):673-90
   PubMed Web of Science ®Google Scholar
• van Blitterswijk M, Baker MC, DeJesus-Hernandez M, et al. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 2013;81(15):1332-41
   PubMed Web of Science ®Google Scholar
• Lashley T, Rohrer JD, Mahoney C, et al. A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. Neuropathol Appl Neurobiol 2014;40(4):502-13
   PubMed Web of Science ®Google Scholar
• Devenney E, Hornberger M, Irish M, et al. Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. JAMA Neurol 2014;71(3):331-9
   PubMed Web of Science ®Google Scholar
• Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11(4):323-30
   PubMed Web of Science ®Google Scholar
• Chio A. ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 1999;246(Suppl 3):III1-5
   PubMedGoogle Scholar
• Smith BN, Newhouse S, Shatunov A, et al. The C9ORF72 expansion mutation is a common cause of ALS +/− FTD in Europe and has a single founder. Eur J Hum Genet 2012;21(1):102-8
   PubMed Web of Science ®Google Scholar
• Stewart H, Rutherford NJ, Briemberg H, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol 2012;123(3):409-17
   PubMed Web of Science ®Google Scholar
• Zou ZY, Li XG, Liu MS, Cui LY. Screening for C9orf72 repeat expansions in Chinese amyotrophic lateral sclerosis patients. Neurobiol Aging 2013;34(6):1710; e5-1710. e6
   PubMed Web of Science ®Google Scholar
• Williams KL, Fifita JA, Vucic S, et al. Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry 2013;84(8):931-5
   PubMed Web of Science ®Google Scholar
• Snowden JS, Harris J, Richardson A, et al. Frontotemporal dementia with amyotrophic lateral sclerosis: a clinical comparison of patients with and without repeat expansions in C9orf72. Amyotroph Lateral Scler Frontotemporal Degener 2013;14(3):172-6
   PubMed Web of Science ®Google Scholar
• Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012;135(Pt 3):693-708
   PubMed Web of Science ®Google Scholar
• Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012;135(Pt 3):736-50
   PubMed Web of Science ®Google Scholar
• Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012;135(Pt 3):794-806
   PubMed Web of Science ®Google Scholar
• Devenney E, Foxe D, Dobson-Stone C, et al. Clinical heterogeneity of the C9orf72 genetic mutation in frontotemporal dementia. Neurocase 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Khan BK, Yokoyama JS, Takada LT, et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry 2012;83(4):358-64
   PubMed Web of Science ®Google Scholar
• Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012;11(3):232-40
   PubMed Web of Science ®Google Scholar
• Bede P, Bokde AL, Byrne S, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology 2013;81(4):361-9
   PubMed Web of Science ®Google Scholar
• Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319(5870):1668-72
   PubMed Web of Science ®Google Scholar
• Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008;40(5):572-4
   PubMed Web of Science ®Google Scholar
• Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011;477(7363):211-15
   PubMed Web of Science ®Google Scholar
• Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10(3):131-46
   PubMed Web of Science ®Google Scholar
• Woolley SC, York MK, Moore DH, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS™). Amyotrophic Lateral Sclerosis 2010;11(3):303-11
   PubMed Web of Science ®Google Scholar
• Lillo P, Mioshi E, Burrell JR, et al. Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One 2012;7(8):e43993
   PubMed Web of Science ®Google Scholar
• Mioshi E, Lillo P, Yew B, et al. Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology 2013;80(12):1117-23
   PubMed Web of Science ®Google Scholar
• Ambikairajah A, Devenney E, Flanagan E, et al. A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotrophic Lateral Sclerosis 2014(0):1-9
   Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double–blind, phase 3 trial. Lancet Neurol 2013;12(11):1059-67
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13(11):1083-91
   PubMed Web of Science ®Google Scholar
• Mazzini L, Ferrero I, Luparello V, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol 2010;223(1):229-37
   PubMed Web of Science ®Google Scholar
• Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008;265(1):78-83
   PubMed Web of Science ®Google Scholar
• Pernet V, Schwab ME. The role of Nogo-A in axonal plasticity, regrowth and repair. Cell Tissue Res 2012;349(1):97-104
   PubMed Web of Science ®Google Scholar
• Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013;12(2):149-56
   PubMed Web of Science ®Google Scholar
• Riboldi G, Zanetta C, Ranieri M, et al. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. Mol Neurobiol 2014;50(3):721-32
   PubMed Web of Science ®Google Scholar
• Su Z, Zhang Y, Gendron TF, et al. Discovery of a biomarker and lead small molecules to target r (GGGGCC)-associated defects in c9FTD/ALS. Neuron 2014;83(5):1043-50
   PubMed Web of Science ®Google Scholar